Pharma BD Deal Intelligence

Biogen Inc. / Alloy Therapeutics, Inc.

2026 · Licensing/Option · Complete

Alloy Therapeutics entered a multi-target collaboration and license agreement granting Biogen rights to its proprietary AntiClastic ASO platform to develop antisense oligonucleotide therapeutics against multiple undisclosed targets. Biogen's Q1 2026 Form 10-Q discloses an accrued upfront payment of $12.0M recognized in acquired IPR&D, upfront and milestone expense. Alloy is eligible for additional milestone payments and tiered royalties; the total deal value was not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Biogen Inc. deals